KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).

Michael E Weinblatt, Peter C Taylor, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, Paula Curtis, Anubha Gupta, Rina Nijhawan, Ciara O'Shea, Kirsty Rayner, Didier Saurigny, Celia Shelton, Millie Wang, Reena Wang, Roy M Fleischmann

BMJ Open 15(3) e088869

PMID40044198
PMCIDPMC11883618
DOI10.1136/bmjopen-2024-088869
发表日期2025-03-05
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: To investigate the long-term safety and efficacy of otilimab, an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody, for patients with rheumatoid arthritis (RA). METHODS: ContRAst X (NCT04333147) was a phase 3, multicentre, long-term extension trial. Patients with RA aged ≥18 years who completed a qualifying contRAst trial (contRAst 1-3) and who the investigator thought might benefit from long-term otilimab treatment were eligible to enter contRAst X. Patients who received otilimab (90 mg/150 mg) in their qualifying trial maintained the same dose; patients who received tofacitinib or sarilumab were rerandomised 1:1 to either otilimab dose. Patients could continue background conventional synthetic disease-modifying antirheumatic drugs. The primary objective was long-term safety (up to 4 years). RESULTS: Of the 2916 patients who entered contRAst X, 2915 received otilimab (exposure range: 7-896 days); the majority were withdrawn due to early trial termination. For otilimab 90 mg and 150 mg, the incidence of adverse events (AEs) was 62% (n=902/1456) and 64% (n=931/1459), the incidence of AEs of special interest was 8% (n=120/1456) and 7% (n=95/1459) and the incidence of serious AEs was 8% (n=123/1456) and 8% (n=114/1459), respectively. There were no instances of pulmonary alveolar proteinosis (PAP), active tuberculosis (TB), TB reactivation or serious hypersensitivity reactions. The proportions of clinical disease activity index low disease activity responders remained relatively stable throughout, with no apparent reduction following the switch from tofacitinib/sarilumab to otilimab. CONCLUSION: No new safety signals or instances of PAP were associated with long-term (≤2.5 years) treatment with otilimab. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT04333147.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。